DermTech, Inc.
NASDAQ:DMTK
Overview | Financials
| Company Name | DermTech, Inc. |
| Symbol | DMTK |
| Currency | USD |
| Price | 0.094 |
| Market Cap | 3,286,522 |
| Dividend Yield | 0% |
| 52-week-range | 0.044 - 3.898 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Mr. Bret Christensen |
| Website | https://www.dermtech.com |
An error occurred while fetching data.
About DermTech, Inc.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD








